Related content

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

By Bolton Ann   Peng Bin   Hubert Martine   Krebs-Brown Axel   Capdeville Renaud   Keller Urs   Seiberling Michael  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 2, 2004-02 ,pp. : 102-106

Springer Publishing Company

Access to resources Recommend Favorite

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects

By Abbas Richat   Chalon Stephan   Leister Cathie   Gaaloul Myriam   Sonnichsen Daryl  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 123-132

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics in Cancer Treatment: Clinical Implications of Interindividual Variability and Drug Interactions

By Boven E.  

American Journal of Cancer, Vol. 1, Iss. 1, 2002-01 ,pp. : 33-53

Adis International

Access to resources Recommend Favorite

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

By Hamilton Marta   Wolf Julie   Drolet Daniel   Fettner Scott   Rakhit Ashok   Witt Karsten   Lum Bert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 613-621

Springer Publishing Company

Access to resources Recommend Favorite

PET in Anti-Cancer Drug Development and Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 3, 2007-11 ,pp. : 259-263

Bentham Science Publishers

Access to resources Recommend Favorite